Trials / Unknown
UnknownNCT03582527
PD-L1 Expression in Advanced Osteosarcoma
The Expression of Programmed Death Ligand-1 (PD-L1) on Advanced Osteosarcoma Tissue and Its Influence on Prognosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | all study participants | patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-12-31
- Completion
- 2020-02-15
- First posted
- 2018-07-11
- Last updated
- 2018-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03582527. Inclusion in this directory is not an endorsement.